TSHA vs. CMPX

Last updated Apr 1, 2026

Compare and contrast key facts about Taysha Gene Therapies, Inc. (TSHA) and Compass Therapeutics Inc. (CMPX).

Performance

TSHA vs. CMPX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Taysha Gene Therapies, Inc. (TSHA) and Compass Therapeutics Inc. (CMPX). The values are adjusted to include any dividend payments, if applicable.

TSHA vs. CMPX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
TSHA Taysha Gene Therapies, Inc.	-18.73%	217.92%	-2.26%	-21.68%	-80.60%	-41.72%
CMPX Compass Therapeutics Inc.	-1.49%	270.34%	-7.05%	-68.99%	58.68%	-62.71%

Fundamentals

Market Cap TSHA : $1.43B CMPX : $977.82M
EPS TSHA : -$0.34 CMPX : -$0.43
PB Ratio TSHA : 5.79 CMPX : 4.97
Total Revenue (TTM) TSHA : $9.77M CMPX : $0.00
Gross Profit (TTM) TSHA : $6.30M CMPX : $0.00
EBITDA (TTM) TSHA : -$108.26M CMPX : -$52.54M

Returns By Period

In the year-to-date period, TSHA achieves a -18.73% return, which is significantly lower than CMPX's -1.49% return.

TSHA

• 1D: 9.83%
• 1M: -1.32%
• YTD: -18.73%
• 6M: 36.70%
• 1Y: 221.58%
• 3Y*: 77.63%
• 5Y*: -26.04%
• 10Y*: —

CMPX

• 1D: 3.73%
• 1M: -6.37%
• YTD: -1.49%
• 6M: 51.14%
• 1Y: 178.42%
• 3Y*: 17.39%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

TSHA vs. CMPX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TSHA

TSHA Risk / Return Rank: 91
TSHA Sharpe Ratio Rank: 93
TSHA Sortino Ratio Rank: 94
TSHA Omega Ratio Rank: 90
TSHA Calmar Ratio Rank: 91
TSHA Martin Ratio Rank: 87

CMPX

CMPX Risk / Return Rank: 91
CMPX Sharpe Ratio Rank: 94
CMPX Sortino Ratio Rank: 89
CMPX Omega Ratio Rank: 88
CMPX Calmar Ratio Rank: 93
CMPX Martin Ratio Rank: 93

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TSHA vs. CMPX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Taysha Gene Therapies, Inc. (TSHA) and Compass Therapeutics Inc. (CMPX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TSHA	CMPX	Difference
Sharpe ratio Return per unit of total volatility	2.35	2.46	-0.11
Sortino ratio Return per unit of downside risk	3.33	2.83	+0.51
Omega ratio Gain probability vs. loss probability	1.40	1.37	+0.03
Calmar ratio Return relative to maximum drawdown	4.23	4.76	-0.54
Martin ratio Return relative to average drawdown	9.01	13.90	-4.89
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TSHA vs. CMPX - Sharpe Ratio Comparison

The current TSHA Sharpe Ratio is 2.35, which is comparable to the CMPX Sharpe Ratio of 2.46. The chart below compares the historical Sharpe Ratios of TSHA and CMPX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	TSHA	CMPX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.35	2.46	-0.11
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.19	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.20	-0.11	-0.09

Correlation

The correlation between TSHA and CMPX is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

TSHA vs. CMPX - Dividend Comparison

Neither TSHA nor CMPX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

TSHA vs. CMPX - Drawdown Comparison

The maximum TSHA drawdown since its inception was -98.14%, which is greater than CMPX's maximum drawdown of -90.91%. Use the drawdown chart below to compare losses from any high point for TSHA and CMPX.

Drawdown Indicators

	TSHA	CMPX	Difference
Max Drawdown Largest peak-to-trough decline	-98.14%	-90.91%	-7.23%
Max Drawdown (1Y) Largest decline over 1 year	-31.13%	-34.82%	+3.69%
Max Drawdown (5Y) Largest decline over 5 years	-97.76%	—	—
Current Drawdown Current decline from peak	-85.92%	-39.89%	-46.03%
Average Drawdown Average peak-to-trough decline	-76.71%	-65.86%	-10.85%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.60%	11.93%	+2.67%

Volatility

TSHA vs. CMPX - Volatility Comparison

Taysha Gene Therapies, Inc. (TSHA) has a higher volatility of 21.10% compared to Compass Therapeutics Inc. (CMPX) at 14.82%. This indicates that TSHA's price experiences larger fluctuations and is considered to be riskier than CMPX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TSHA	CMPX	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.10%	14.82%	+6.28%
Volatility (6M) Calculated over the trailing 6-month period	65.51%	42.80%	+22.71%
Volatility (1Y) Calculated over the trailing 1-year period	99.28%	73.21%	+26.07%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	136.33%	83.91%	+52.42%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	131.85%	83.91%	+47.94%

Financials